# PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer

> **NCT03176264** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** PDR001
- **DRUG:** bevacizumab
- **DRUG:** mFOLFOX6

## Key facts

- **NCT ID:** NCT03176264
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-25
- **Primary completion:** 2018-01-30
- **Final completion:** 2018-01-30
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** The study was terminated early due to company decision.
- **Last updated:** 2021-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03176264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03176264, "PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03176264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*